Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 13/20 | 0.63 |
| ▸ | STK17B | O94768 | 7/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5414085 | 0.89 | STK17A (0.56) | STK17ASTK17BPRKCQMEN1CYP1A2 | |
| SCHEMBL1916444 | 0.89 | STK17A (0.60) | STK17ASTK17BPRKCQMEN1CYP1A2 | |
| SCHEMBL5416081 | 0.88 | STK17A (0.61) | STK17ASTK17BPRKCQMEN1CYP1A2 | |
| SCHEMBL5408700 | 0.88 | STK17A (0.80) | STK17ASTK17BL3MBTL1PRKCQMEN1 | |
| SCHEMBL1918649 | 0.88 | STK17A (0.59) | STK17ASTK17BL3MBTL1PRKCQMEN1 | |
| SCHEMBL1917646 | 0.87 | STK17A (0.60) | STK17ASTK17BPRKCQMEN1CYP1A2 | |
| SCHEMBL3288525 | 0.87 | STK17A (0.57) | STK17ASTK17BPRKCQMEN1CYP1A2 | |
| SCHEMBL1917036 | 0.87 | STK17A (0.57) | STK17ASTK17BPRKCQMEN1CYP1A2 | |
| SCHEMBL3283925 | 0.85 | STK17A (0.57) | STK17ASTK17BPRKCQMEN1CYP1A2 | |
| SCHEMBL3284017 | 0.84 | STK17A (0.57) | STK17ASTK17BPRKCQMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166599-B2 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-23 | — | — | US | disclosed |
| US-20050090486-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-04-28 | — | — | US | disclosed |
| US-20030134838-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134838-A1 | Trisubstituted pyrimidines | APP, PSEN1, BACE1 | STK17A 3301/4885STK17B 3455/4885L3MBTL1 3293/4885 |
| US-20050090486-A1 | Trisubstituted pyrimidines | APP, BACE1, PSEN1 | STK17A 3456/4885STK17B 3502/4885L3MBTL1 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.